MCS · Marcus

The thesis

The Marcus Corporation's shares are modestly more likely to beat the S&P 500 over the next three months, because its theatre recovery carried through the fiscal third quarter and the hotel division still has 2027 bookings ahead. The 18 December 2026 release of Avengers: Doomsday and the fiscal fourth-quarter report, expected in late February 2027, settle whether the recovery runs through the holiday quarter.

The 29 October 2026 earnings release reported comparable theatre attendance up 16.8%, revenue of $237.8 million (up 13.1%) and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $49.1 million (up 21.5%). Earnings Whispers reported the same day that management expects the November box office to fall from a year earlier.

The shares closed at $27.22 on 12 November 2026, up from $26.76 on 6 November 2026 after closes of $26.99, $27.20 and $27.40 on the three sessions between. They remain 9.0% lower than three months earlier. The market has priced in a soft November: the close sits 16.0% below the 3 August 2026 high of $32.42 but well above the 200-day average, so most of the year's recovery from the $14.75 closing low of 20 November 2025 is still in the price.

Bullish and bearish views on The Marcus Corporation

The bull case on The Marcus Corporation (MCS), in brief: attendance accelerated from the second quarter. The bear case: November attendance faces a decline.

Bull case

• Attendance accelerated from the second quarter. The 29 October 2026 release reported comparable theatre attendance up 16.8%, against 10.9% in the fiscal second quarter. Same-store admission revenue rose 21.8%, and concession revenue per person rose 3.8%.
• Theatre profit outgrew theatre revenue. Fiscal third-quarter theatre revenue was $145.0 million, up 20.9%, and division adjusted EBITDA was $32.3 million, up 46.3%, per the release.
• Cash generation strengthened the balance sheet. Nine-month operating cash flow was $77.2 million against $35.4 million a year earlier, per the release. Cash reached $60.2 million at 30 September 2026, and Earnings Whispers reported net leverage of 0.8 times, down from 1.7 times in the fiscal first quarter.
• Capital spending is coming down. Earnings Whispers reported on 29 October 2026 that fiscal 2026 capital spending guidance was cut to $45–50 million from $50–55 million. Management also named theatre acquisitions as a possible use of cash.
• December has a major release. Disney confirmed a 18 December 2026 US release for Avengers: Doomsday, and Earnings Whispers reported management citing strong presales for it.
• Hotel bookings for 2027 are ahead. Earnings Whispers reported 2027 group room pace up 10% and banquet and catering pace up 14% as of the 29 October 2026 call.
• Analysts remain constructive. A 3 November 2026 headline reported Wedbush trimming its target to $32, still above the close of $27.22 on 12 November 2026. A 2 November 2026 headline reported Barrington Research raising its target. The company declared its regular quarterly dividend on 4 November 2026.

Bear case

• November attendance faces a decline. Management expects the November box office to fall from a year earlier, per Earnings Whispers on 29 October 2026. The Thanksgiving weekend is the first test of how far.
• Marcus lost ground to the national box office. Earnings Whispers reported Marcus trailing the national box office by about 1.4 points in the fiscal third quarter, after outperforming by 4.8 points in the fiscal first quarter and 7.6 points in the fiscal fourth quarter of 2025.
• Ticket price growth is fading. Average ticket price rose 4.3% in the fiscal third quarter, against 7.8% in the first quarter and 12.7% in the fourth quarter of 2025, per Earnings Whispers.
• Hotel growth slowed sharply. Owned-hotel revenue per available room (RevPAR) rose 2.1% in the fiscal third quarter against 13.9% in the second quarter, per the release. Division adjusted EBITDA fell $0.6 million to $22.6 million, and Earnings Whispers reported RevPAR 5.7 points behind the national upper-upscale segment.
• A large holder sold shares. SEC Form 4 filings show director and 10% owner Diane M. Gershowitz sold 50,000 shares on the open market at $27.61 on 23 September 2026.
• Earnings missed one compiler's estimate. Earnings Whispers recorded diluted earnings per share of $0.60 against a $0.62 consensus, while Benzinga reported a beat against $0.56.

Price setup

The shares closed at $27.22 on 12 November 2026. That is below the 50-day average of $27.62 and above the 200-day average of $22.43, both from adjusted closes as of the same session. The three-month change is −9.0%, measured from the adjusted close of $29.91 on 14 August 2026.

The 52-week high is $32.42, reached intraday on 3 August 2026. The 6 November 2026 close of $26.76 is the recent low among the closes of the past week, and the 12 November 2026 close sits above it.

The next earnings report is more than three months away. The only insider transaction in recent SEC filings is the 23 September 2026 sale noted above; no other Form 4 sales appear in the filings.

Catalysts ahead

• ~27 November 2026 (est.): Thanksgiving holiday box office weekend. It is the first read on whether November attendance falls as far as management guided on 29 October 2026.
• 18 December 2026: US theatrical release of Avengers: Doomsday. Management cited strong presales; the holiday quarter's attendance comparison depends heavily on this release.
• 31 December 2026: Fiscal fourth quarter of 2026 ends. The quarter tests whether attendance gains outlast the summer slate and whether hotel RevPAR growth recovers from 2.1%.
• ~25 February 2027 (est.): Fiscal fourth-quarter 2026 results, estimated from the 26 February 2026 date of last year's release. The report settles whether comparable attendance kept growing, whether Marcus regained ground on the national box office, and whether hotel RevPAR stayed positive.

What would change the view

A daily close below $26.00, which would sit under the 6 November 2026 close of $26.76 and show the shares giving up the recovery. Fiscal fourth-quarter comparable theatre attendance or owned-hotel revenue per available room below a year earlier would also show the case failing.

The risks this note tracks, each with what would confirm it:

• A weak November slate turns fiscal fourth-quarter theatre attendance negative despite the December release. Confirmed by: a decline from a year earlier in comparable theatre attendance in the fiscal fourth-quarter 2026 report.
• Marcus keeps losing ground to the national box office as major films skew toward coastal markets. Confirmed by: a gap wider than 1.4 points behind the national box office in the fiscal fourth-quarter 2026 results or call.
• Hotel growth turns negative after slowing from 13.9% RevPAR growth in the fiscal second quarter to 2.1% in the third. Confirmed by: a decline from a year earlier in owned-hotel RevPAR or hotel revenue in the fiscal fourth-quarter 2026 report.
• Analyst expectations fall further after Wedbush trimmed its target to $32 on 3 November 2026. Confirmed by: additional target cuts from covering firms before the fiscal fourth-quarter report, or lower estimates after the Thanksgiving box office.

What it trades with

The theatre division moves with the national film slate, so the shares respond to major release weekends and to the results of other US cinema operators. The hotel division is tied to Midwest travel and group demand, which management said high gas prices and airfares could pressure. The two divisions are reported separately and moved in opposite directions in the fiscal third quarter, so consolidated figures can hide a weakening segment.